Managing the risks of androgen deprivation therapy in prostate cancer

+Print Archive
PRACTICE

Managing the risks of androgen deprivation therapy in prostate cancer

Chris Ellis

Chris Ellis

ECG heartbeat 12/2/20

HEARTBEAT

Cardiologist Chris Ellis reviews the assessment and management of cardiovascular disease risk in a patient with metastatic prostate cancer but no cardiovascular symptoms

Key points, The most common cause of death for men with prostate cancer is now cardiovascular disease. Androgen deprivation therapy is used to reduce serum test